What is Brookline Cap M’s Estimate for MRKR Q2 Earnings?

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities researchers at Brookline Cap M issued their Q2 2026 EPS estimates for Marker Therapeutics in a research note issued on Wednesday, March 18th. Brookline Cap M analyst L. Cann forecasts that the company will earn ($0.27) per share for the quarter. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings results on Wednesday, March 18th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.17. The firm had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative return on equity of 84.13% and a negative net margin of 343.03%.

A number of other research analysts also recently weighed in on the company. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. HC Wainwright started coverage on shares of Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective on the stock. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, UBS Group restated a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.25.

Marker Therapeutics Trading Down 1.5%

NASDAQ:MRKR opened at $1.32 on Friday. The company has a 50 day simple moving average of $1.60 and a two-hundred day simple moving average of $1.29. The company has a market cap of $22.00 million, a PE ratio of -1.55 and a beta of 1.42. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.07.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently made changes to their positions in the business. Osaic Holdings Inc. lifted its holdings in Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Marker Therapeutics by 16.4% in the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after buying an additional 17,400 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Marker Therapeutics during the second quarter worth $33,000. LPL Financial LLC grew its stake in Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after acquiring an additional 24,500 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Marker Therapeutics in the 3rd quarter valued at $25,000. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.